BridgeBio Pharma BBIO Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's increase (decrease) in prepaid expense and other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's increase (decrease) in prepaid expense and other assets?
- BridgeBio Pharma (BBIO) reported increase (decrease) in prepaid expense and other assets of $18.85M in Q1 2026.
- How has BridgeBio Pharma's increase (decrease) in prepaid expense and other assets changed year-over-year?
- BridgeBio Pharma's increase (decrease) in prepaid expense and other assets increased by 3769.6% year-over-year, from $487K to $18.85M.
- What is the long-term trend for BridgeBio Pharma's increase (decrease) in prepaid expense and other assets?
- Over 2 years (2021 to 2023), BridgeBio Pharma's increase (decrease) in prepaid expense and other assets has grown at a -20.4% compound annual growth rate (CAGR), from $4.26M to $2.7M.